Clinical Research Directory

Inclusion Criteria: 1. Patients aged from 18 to 80 years old; 2. patients with NSCLC confirmed by needle aspiration cytology or surgical pathology, who cannot undergo radical surgery due to recurrence, metastasis or patient's own conditions; 3. Has completed 2-4 cycles of first-line therapy (including chemotherapy, immunotherapy, chemotherapy combined with immunotherapy, chemotherapy combined with targeted therapy, etc.), and has SD assessed by RECIST 1.1 during the same period; 4. Patients had at least one measurable lesion; 5. No local radiotherapy for primary or metastatic lesions within 28 days; 6. ECOG score 0-2; 7. Expected survival time ≥3 months; 8. Voluntarily participate and sign informed consent. Exclusion Criteria: 1. Women who plan to become pregnant within 6 months, or are pregnant or lactating. 2. Patients with severe brain or bone metastases; 3. Severe anemia and severe liver and kidney damage; 4. Pathological or long-term follow-up results may not be available; 5. The relevant control imaging data and clinical data were not available; 6. Severe illness is difficult to cooperate (such as acute cardiovascular and cerebrovascular events or serious cardiovascular diseases); 7. Received any surgery or invasive treatment or procedure within 4 weeks before enrollment; 8. Cannot tolerate standard second-line therapy or other first-line therapies. 9. Known allergy to 99mTc-H7ND or any of its components; He had a history of severe allergies; 10. Protocol imaging contraindications were present; 11. The investigator considered it inappropriate to participate in the study.